Position
Fidelity in Rapport Therapeutics, Inc.
Back to the book · All holders of RAPP
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $74.4M$31.29 → $41.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 7.11M | $215.8M | — | — | — | 0.0% |
| Q1 2026 | 7.17M | $224.3M | $31.29 | $6.76M | $1.79M | 0.0% |
| Q2 2026 | 7.17M | $298.9M | $41.67 | $74.4M | $164.8K | 0.0% |